OncoSec Signs Research Agreement with Duke University School of Medicine to Evaluate the Combination of TAVOPLUS with a HER2-Plasmid Vaccine

 OncoSec Signs Research Agreement with Duke University School of Medicine to Evaluate the Combination of TAVOPLUS with a HER2-Plasmid Vaccine

OncoSec Signs Research Agreement with Duke University School of Medicine to Evaluate the Combination of TAVOPLUS with a HER2-Plasmid Vaccine

Shots:

  • Duke University to conduct preclinical studies using HER2-plasmid vaccines + TAVOPLUS (IL-12 plasmids) for HER2+ breast cancer. OncoSec to provide its TAVO and APOLLO (new electroporation generator) to Duke University’s to increase DNA-plasmid cellular transfection rates using lower voltage and a longer pulse width 
  • Duke to utilize OncoSec’s TAVO with high-intensity ultrasound tumor ablation models for assessing the impact of IL-12 delivery on the development of systemic immunity
  • TAVO (tavokinogene telseplasmid) is immunotherapy enabling intratumoral delivery of DNA-based IL-12, currently being evaluated for metastatic melanoma and triple negative breast cancer. OncoSec is also developing DNA-encoded therapeutic candidates & tumor indications for use with its ImmunoPulse platform

Click here to read full press release/ article | Ref: OncoSec | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post